ArticleBMC women's health2026
Plasma proteomic biomarkers for predicting chemoradiation response in locally advanced cervical cancer.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundA significant proportion of patients with locally advanced cervical cancer (LACC) experience treatment failure following concurrent chemoradiation therapy (CRT). Identifying patients who are unlikely to respond to CRT may inform personalized treatment strategies.
methodsWe evaluated plasma proteomic profiles of 39 patients with LACC stratified by CRT response: complete response (CR), partial response/stable disease (PR/SD), and progressive disease (PD). The primary objective was to identify protein differences between complete responders (CR) vs. non-responders (PR/SD and PD). Secondary objectives included subclass analyses (CR vs. PR/SD vs. PD). Nano-liquid chromatography-tandem mass spectrometry with data-independent acquisition (nano-LC MS/MS-DIA) was used and verified by parallel reaction monitoring. Differential expression between CRT response groups was assessed using a Bayesian moderated t-test with minimal probabilistic imputation. RNA-seq data from The Cancer Genome Atlas were analyzed using DESeq2, with functional enrichment performed via clusterProfiler and coexpression networks built with NetworkAnalyst. Nested t-test with ridge regression with 2,000 bootstrap iterations was used to evaluate predictive performance, and model discrimination was assessed by AUC using R.
resultsWe identified 507 protein groups. Of these, 407 were consistently detected in > 50% of samples. The primary analysis identified eight proteins significantly downregulated in non-responders involved in inflammatory response pathways. Secondary subclass analysis demonstrated distinct proteomic dysregulation in patients with PR/SD compared to CR groups, but not in patients with PD, with enrichment of pathways related to complement activation, NF-κB signaling, and lipid metabolism. Targeted verification of secondary findings using parallel reaction monitoring confirmed a panel of 13 proteins that robustly distinguished PR/SD from CR, yielding an optimism-corrected area under the curve of 0.832 (95% confidence interval of bootstrapped models: 0.789–0.957). Additionally, exploratory integration with tumor RNA-seq data from The Cancer Genome Atlas revealed coordinated dysregulation in pathways involving hypoxia inducible-factor 1 signaling, proteoglycan and choline metabolism, and the complement and coagulation cascade.
conclusionsBaseline plasma protein profiles found only modest differences between overall responder and non-responders. Nevertheless, secondary analyses suggested exploratory potential of proteins in predicting PR/SD to CRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.